Search
Boston Scientific Corp
BSXAdd to Watchlist
44.205USD
-0.255-0.57%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
65.70BMarket Cap
18.39P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.57%
5 Days
-2.40%
1 Month
-23.49%
6 Months
-54.02%
Year to Date
-53.64%
1 Year
-57.61%
Key Figures
44.210Open
45.280High
19.82MVolume
18.39P/E TTM
11.95P/E Dynamic
--Dividend TTM
1.33%Turnover Ratio
44.460Prev. Close
43.890Low
489.30MTurnover
35.46P/E Static
2.54P/B
0.00%Div Yield TTM
8.42%ROA
109.50052wk High
0.92Volume Ratio
1.85BNet Profit
1.49BShares
2.4044EPS TTM
0.58Beta
14.83%ROE
48.41052wk Low
3.13%Amplitude
64.89%Gross Margin
65.70BMarket Cap
-7.95Reward/Risk
1.50%Risk Rate
TradingKey Stock Score of Boston Scientific Corp
Currency: USD Updated: 2026-06-24Key Insights
Boston Scientific Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 79.68.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Boston Scientific Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
44°C
Very Low
Very High
Negative
Boston Scientific Corp Highlights
StrengthsRisks
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 40.97% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 20.07B.
Undervalued
The company’s latest PE is 18.49, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.40B shares, decreasing 1.09% quarter-over-quarter.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 5.22M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.34.
Analyst Rating
Based on
35
analysts
Buy
Current Rating
78.620
Target Price
+72.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Boston Scientific Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Boston Scientific Corp Info
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Ticker SymbolBSX
CompanyBoston Scientific Corp
CEOMahoney (Michael F)
Websitehttps://www.bostonscientific.com/en-US/Home.html
Related Instruments
+2.48%
+2.79%
+3.08%
-0.53%
+2.39%
+2.80%
+0.84%
+0.51%
-0.20%
+0.93%
+0.93%
+0.87%
+0.11%
+3.92%
+1.05%
+2.49%
+2.97%
+0.30%
+0.29%Popular Instruments
51913.400
-111.300 (-0.21%)
29204.300
-250.700 (-0.85%)
7335.300
-31.500 (-0.43%)
15404.000
-347.000 (-2.20%)
69845.000
-1287.000 (-1.81%)
6232.800
-33.000 (-0.53%)
71.118
-0.226 (-0.32%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4016.260
-9.890 (-0.25%)
FAQs
What is the current price of Boston Scientific Corp (BSX)?
The current price of Boston Scientific Corp (BSX) is 44.20.
What is the symbol of Boston Scientific Corp?
The ticker symbol of Boston Scientific Corp is BSX.
What is the 52-week high of Boston Scientific Corp?
The 52-week high of Boston Scientific Corp is 109.50.
What is the 52-week low of Boston Scientific Corp?
The 52-week low of Boston Scientific Corp is 48.41.
What is the market capitalization of Boston Scientific Corp?
The market capitalization of Boston Scientific Corp is 65.70B.
Is Boston Scientific Corp (BSX) currently rated as Buy, Hold, or Sell?
According to analysts, Boston Scientific Corp (BSX) has an overall rating of Buy, with a price target of 78.62.
What is the Earnings Per Share (EPS TTM) of Boston Scientific Corp (BSX)?
The Earnings Per Share (EPS TTM) of Boston Scientific Corp (BSX) is 1.96.
